© 2020 MJH Life Sciences™ and . All rights reserved.
Pimecrolimus Impresses
July 1, 2001
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.